Ex vivo expansion of TILs is a process where lymphocytes that have successfully infiltrated and recognized TAAs on tumor cells are removed from patients, expanded through treatment with T-cell growth factors IL-2, IL-7 or IL-21, and, once reaching sufficient population size, readministered to the patient. The gene discussed is IL2; the disease is neoplasm.